Meet us at AASLD, booth #1041 to learn how our deep expertise in imaging-based hepatic biomarkers and global operational support help sponsors optimise trial design and accelerate the delivery of MASH treatments to patie...
Preparing for ICH GCP E6(R3) implementation
A guide to assessing the impact, risk and requirements of the change
Read the whitepaperMeeting requirements for Joint Clinical Assessments
A planning guide for health technology developers
Read the whitepaper
Featured solutions
Blended solutions
Bespoke, seamless solutions to meet unique sponsor challenges.
Outcome Measures
A multi-faceted approach to identifying, selecting, and implementing evidence-based measures that matter to patients.
Biotech
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Cardiac Safety Solutions
End-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO and MUGA studies.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Market Access
Expertise in mission-critical pricing, market access, and reimbursement.
Specialty Laboratory Solutions
Supporting precision medicine programs across all phases of drug diagnostic co-development.
Videos
ICON overview
ICON is expanding the possibilities of clinical research for customers, partners, and patients.
Biotech
Developing transformative therapies with small & mid-sized biopharma companies requires a flexible approach.
Technology solutions
ICON’s technology solutions are focused on the factors most critical to our customers.
AI @ICON
ICON is harnessing AI with pragmatic, impactful, award winning solutions for a healthier world.
Obesity
ICON has the cross functional expertise to help sponsors overcome the challenges associated with obesity research.
Webinars
Beyond the bench: The advantages of GMP over USP compounding in early phase development
6 November 2025. Register now.
Strategic approaches for early clinical trials in neurodegenerative diseases
18 November 2025. Register now.
Riding the data wave: How pharma can navigate disruptions in open claims
8 December 2025. Register now.
